11/18/2026 | Press release | Distributed by Public on 11/18/2026 18:44
Today's big story: Could Nvidia Stock Fall 50%? Follow The Cash
Natera (NTRA) stock fell 9.6% on Monday, November 16, 2026, while the S&P 500 lost 1.9%. The company had no earnings report or filing around the move. Over the weekend, its CFO defended the immediate transition to a new CEO. Meanwhile, 21 of the 22 other companies of $2 billion or more in its sub-industry, life sciences tools and services, fell the same day. What was hitting the market that Monday?
Natera Fell On A Day Chip Stocks Slid
The Nasdaq Composite dropped 2.5% that Monday, a steeper fall than the S&P 500. Chip makers such as AMD and Intel slid ahead of two big tests for the AI trade. Those were Nvidia's results on Tuesday and Anthropic's expected trading debut on Thursday.
Natera does not make chips. The company sells tests in cancer, women's health and organ health. In the third quarter of fiscal 2026, revenue rose 34.1% from a year earlier. Natera posted an operating loss of $68.3 million in that quarter, narrower than the $97.6 million loss a year earlier.
During the November 5 earnings call, management set a goal of doubling revenue over the next three years to reach $6 billion in 2029.
Did Natera Fall With Life Sciences Stocks?
It did, and by far more. The median decline for the 22 other life sciences tools and services companies was 1.3%, with five of them dropping 5% or more. Only one of the 22 rose. The health care sector ETF, XLV, slipped 0.5%.
In its peer group, Guardant Health fell 5.1% and Illumina 4.4%, while Labcorp and Quest Diagnostics rose. That peer list is a different group from the 22 sub-industry companies counted above. Natera's drop was more than seven times the median for its sub-industry.
Where Natera Stock Stands After The Drop
Natera stock recorded three falls at least this large in the prior 365 days. The latest occurred on November 6, the day after its third-quarter call, when shares dropped 14.6%.
Over the month to November 16, the stock lost 26.7%, compared with a 3.1% loss for the S&P 500. Shares closed at $288.48, against a 52-week closing high of $436.00 on October 29. The lowest close of the past year was $182.65 on March 27. Over twelve months, the shares are still up 43.8%, compared to 11.4% for the S&P 500.
Natera trades at 14.3 times its sales over the past twelve months, compared with 3.2 times for the S&P 500. The company next reports its fourth quarter of fiscal 2026. Clinical units of its cancer test, Signatera, reached about 316 thousand in the third quarter. That count is the measure to watch in the next report.
Natera had no news of its own on November 16, and its shares still fell far more than the market and its sub-industry. No one can see a day like that coming. But you can build a portfolio in which one stock's fall is only a small part of the whole.
Stop Guessing. Start Positioning.
No one can predict surprises like this one. The Trefis High Quality (HQ) Portfolio doesn't try: it holds 30 quality stocks in equal weight, so no single surprise decides your result. Come see how it works.
Spot an error or want more like this? Tell us in 10 seconds.